EA200970045A1 - PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BADLY SOLUBLE IN WATER ACTIVE SUBSTANCE - Google Patents

PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BADLY SOLUBLE IN WATER ACTIVE SUBSTANCE

Info

Publication number
EA200970045A1
EA200970045A1 EA200970045A EA200970045A EA200970045A1 EA 200970045 A1 EA200970045 A1 EA 200970045A1 EA 200970045 A EA200970045 A EA 200970045A EA 200970045 A EA200970045 A EA 200970045A EA 200970045 A1 EA200970045 A1 EA 200970045A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
oral administration
active substance
water active
alkaline
Prior art date
Application number
EA200970045A
Other languages
Russian (ru)
Inventor
Раджеш Джаин
Коур Ч. Джиндал
Амарджит Сингх
Муниш Талвар
Хенрикус Р.М. Гориссен
Original Assignee
Солвей Фармасьютикалс Б.В.
Панацея Биотек Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В., Панацея Биотек Лтд. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200970045A1 publication Critical patent/EA200970045A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Настоящее изобретение предоставляет улучшенные пероральные фармацевтические композиции, включающие по меньшей мере одно плохо водорастворимое активное средство, предпочтительно ингибитор фермента конверсии эндотелина (ЕСЕ) и/или ингибитор нейтральной эндопептидазы (NEP) в количестве, большем чем 10% мас./мас. композиции, более предпочтительно щелочная система включает смесь по меньшей мере двух щелочных соединений в соотношении от 1:20 до 20:1, причем активным средством является SLV-306 или его фармацевтически приемлемые соли, сложные эфиры, гидраты, сольваты, изомеры или их производные; щелочную систему в количестве, большем чем 10% мас./мас. композиции, предпочтительно включающего смесь по меньшей мере двух щелочных соединений и необязательно одно или более фармацевтически приемлемых вспомогательных средств. Также изобретение предоставляет способ для получения таких улучшенных композиций и способ использования такой композиции.The present invention provides improved oral pharmaceutical compositions comprising at least one poorly water-soluble active agent, preferably an endothelin conversion enzyme inhibitor (ECE) and / or a neutral endopeptidase inhibitor (NEP) in an amount of more than 10% w / w. compositions, more preferably an alkaline system, comprises a mixture of at least two alkaline compounds in a ratio of from 1:20 to 20: 1, the active agent being SLV-306 or its pharmaceutically acceptable salts, esters, hydrates, solvates, isomers or their derivatives; alkaline system in an amount greater than 10% wt./wt. a composition, preferably comprising a mixture of at least two alkaline compounds and optionally one or more pharmaceutically acceptable adjuvants. The invention also provides a method for preparing such improved compositions and a method for using such a composition.

EA200970045A 2006-06-22 2007-06-21 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BADLY SOLUBLE IN WATER ACTIVE SUBSTANCE EA200970045A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81557906P 2006-06-22 2006-06-22
IN1473DE2006 2006-06-22
EP06115881 2006-06-22
PCT/EP2007/056207 WO2007147873A1 (en) 2006-06-22 2007-06-21 Oral pharmaceutical composition of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
EA200970045A1 true EA200970045A1 (en) 2009-06-30

Family

ID=38475974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970045A EA200970045A1 (en) 2006-06-22 2007-06-21 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BADLY SOLUBLE IN WATER ACTIVE SUBSTANCE

Country Status (9)

Country Link
EP (1) EP2037890A1 (en)
JP (1) JP2009541267A (en)
KR (1) KR20090033246A (en)
AU (1) AU2007263016A1 (en)
CA (1) CA2654243A1 (en)
EA (1) EA200970045A1 (en)
IL (1) IL195653A0 (en)
NO (1) NO20090265L (en)
WO (1) WO2007147873A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087621A1 (en) * 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
AR038681A1 (en) * 2002-02-14 2005-01-26 Solvay Pharm Bv ORAL FORMULATION OF SOLID SOLUTION OF A POVERLY SOLUBLE ACTIVE SUBSTANCE IN WATER
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders

Also Published As

Publication number Publication date
KR20090033246A (en) 2009-04-01
AU2007263016A1 (en) 2007-12-27
NO20090265L (en) 2009-01-22
EP2037890A1 (en) 2009-03-25
CA2654243A1 (en) 2007-12-27
WO2007147873A1 (en) 2007-12-27
IL195653A0 (en) 2009-09-01
JP2009541267A (en) 2009-11-26

Similar Documents

Publication Publication Date Title
ES2606342T3 (en) Compositions for oral care of stannous salt and sodium tripoli phosphate and methods
CO5630034A2 (en) PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
RS53155B (en) Administration of dipeptidyl peptidase inhibitors
EE05103B1 (en) Pharmaceutical formulations containing azetidine derivatives, azetidine derivatives and methods for their preparation
IL179718A0 (en) Pharmaceutical composition containing irbesartan
EA200100972A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS PROTEAS INHIBITORS
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
NO20002133L (en) Solid state solutions and dispersions of weakly water-soluble drugs
WO2006118948A3 (en) Therapeutic compositions
UY27320A1 (en) NEW PHARMACEUTICAL COMPOSITIONS
HK1076605A1 (en) Formulations
WO2008060934A8 (en) Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
UA89684C2 (en) Two-layer pharmaceutical dosed out form with modified liberation of nimesulide
MX2007006635A (en) Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition.
NO20083027L (en) Controlled release solid formulation
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BR0207872A (en) Active agent release compound, composition, unit dosage form and method of administration
TW200621773A (en) Bicyclononene derivatives
TW200833371A (en) Process for solid formulations
MX2013001637A (en) Oral controlled release pharmaceutical compositions of blonanserin.
WO2008065485A3 (en) Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
BR0311642A (en) Increased Release Sodium Divalproex Formulation
EA200970045A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BADLY SOLUBLE IN WATER ACTIVE SUBSTANCE
WO2007069274A3 (en) Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent